MabVax begins dosing of MVT-1075 in Phase I cancer therapy trial

US-based biotechnology firm MabVax Therapeutics has started dosing patients in a Phase I clinical trial of MVT-1075 to treat patients with CA19-9 positive malignancies such as pancreatic, colon and lung cancers.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Conclusion: Molecular mechanism and clinical efficacy of some of the emerging molecular targets for cancer chemotherapy have been briefly reviewed in the present article.
Source: Current Chemical Biology - Category: Biochemistry Source Type: research
Publication date: Available online 10 July 2018Source: Journal of Pharmacological SciencesAuthor(s): Qin Chen, Haoran Zhang, Meng Wu, Qin Wang, Lusong Luo, Haikuo Ma, Xiaohu Zhang, Sudan HeAbstractAberrant activation of Hedgehog (Hh) signaling is associated with the development of numerous human cancers. Vismodegib is the first Hh inhibitor approved for anti-cancer therapy by targeting Smoothened (SMO), a critical regulator of the Hh pathway. However, acquisition of drug resistance to vismodegib occurs overtime. Apoptosis is a prevalent form of programmed cell death that is executed by caspases. Induction of tumor cell apo...
Source: Journal of Pharmacological Sciences - Category: Drugs & Pharmacology Source Type: research
In this study, we evaluated the value of SCD1 as a candidate therapeutic target in human endometrial cancer. Compared with secretory and post-menopausal endometrium, SCD1 was highly expressed in normal endometrium of proliferative phase, endometrial hyperplasia and endometrial carcinoma, while was absent or low expression in non-malignant control stromal cells and adjacent normal endometrium. Knockdown of SCD1 significantly repressed endometrial cancer cell growth and induced cell apoptosis. Both short hairpin RNA targeted knockdown and chemical inhibitor of SCD1 suppressed the foci formation of AN3CA, a metastatic endomet...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Abstract A novel series of enediynes possessing pentafluorophenylsulfoxide have been developed. The innovative compounds possess antiproliferative activity against a broad panel of human cancer cells originating from breast, blood, lung, kidney, colon, prostate, pancreas or skin with IC50 ranging from 0.6 to 3.4 μM. The antiproliferative activity of enediynes in darkness is associated to their ability to compromise microtubule network. In addition, exposure to UV leads to double-stranded DNA cleavage caused by the newly synthesized molecules reducing further their IC50 in nanomolar range against human tumor c...
Source: European Journal of Medicinal Chemistry - Category: Chemistry Authors: Tags: Eur J Med Chem Source Type: research
Authors: Skoda AM, Simovic D, Karin V, Kardum V, Vranic S, Serman L Abstract The Hedgehog (Hh) signaling pathway was first identified in the common fruit fly. It is a highly conserved evolutionary pathway of signal transmission from the cell membrane to the nucleus. The Hh signaling pathway plays an important role in the embryonic development. It exerts its biological effects through a signaling cascade that culminates in a change of balance between activator and repressor forms of glioma-associated oncogene (Gli) transcription factors. The components of the Hh signaling pathway involved in the signaling transfer t...
Source: Bosnian Journal of Basic Medical Sciences - Category: General Medicine Tags: Bosn J Basic Med Sci Source Type: research
BACKGROUNDThe improving efficacy of cancer treatment has resulted in an increasing array of treatment‐related symptoms and associated burdens imposed on individuals undergoing aggressive treatment of their disease. Often, clinical trials compare therapies that have different types, and severities, of adverse effects. Whether rated by clinicians or patients themselves, it can be difficult to know which side effect profile is more disruptive or bothersome to patients. A simple summary index of bother can help to adjudicate the variability in adverse effects across treatments being compared with each other. METHODSAcross 4 ...
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
Growing evidence suggests that microbes can influence the efficacy of cancer therapies. By studying colon cancer models, we found that bacteria can metabolize the chemotherapeutic drug gemcitabine (2',2'-difluorodeoxycytidine) into its inactive form, 2',2'-difluorodeoxyuridine. Metabolism was dependent on the expression of a long isoform of the bacterial enzyme cytidine deaminase (CDDL), seen primarily in Gammaproteobacteria. In a colon cancer mouse model, gemcitabine resistance was induced by intratumor Gammaproteobacteria, dependent on bacterial CDDL expression, and abrogated by cotreatment with the antibiotic ciprofloxa...
Source: ScienceNOW - Category: Science Authors: Tags: Medicine, Diseases reports Source Type: news
The leading cause of death in cancer survivors is cardiovascular disease, in part due to cancer therapy-induced cardiotoxicity. The short- and long-term cardiovascular side effects of a newer class of targeted chemotherapy, mTOR inhibitors, have not been well established as they have been with anthracyclines, anti-VEGF therapy and tyrosine kinase inhibitors. mTOR inhibitor Everolimus, used as an agent in transplant immunosuppression, is now indicated for the treatment of metastatic breast, colon, renal cell and pancreatic cancer. Retrospective clinical data indicate the possibility of heart failure and hypertension as card...
Source: Hypertension - Category: Cardiology Authors: Tags: Poster Abstract Presentations Source Type: research
Abstract In the last few years, exciting reports have emerged regarding the role of the two types of neurotrophin receptors, p75(NTR) and Trks, not only in neurons, where they were discovered, but also in non-neural cells and, especially, in numerous cancers, including breast, lung, colon-rectum, pancreas, prostate, glioblastoma, neuroblastoma, myeloma, and lymphoid tumors. Traditionally, p75(NTR), activated by all neurotrophins and their precursors, is an inhibitor. In various cancers, however, activated p75(NTR) induces variable effects, from inhibition to stimulation of cell proliferation, dependent on their di...
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Tags: Rev Physiol Biochem Pharmacol Source Type: research
In conclusions, although studies in this feld are rare and inconsistence, recent fndings have demonstrated that KD can potentially inhibit the malignant cell growth and increase the survival time. Because of differences physiology between animals and humans, future studies in cancer patients treated with a KD are needed.Keywords:Cancer, ketogenic diet, survival, tumor growth
Source: International Journal of Preventive Medicine - Category: International Medicine & Public Health Source Type: research
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Clinical Trials | Colon Cancer | Colorectal Cancer | Pancreas | Pancreatic Cancer | Pharmaceuticals